WAL0921

N/A

Report date: 2026/03/26 20:00:17

Base Information

Drug NameWAL0921
Drug Alias NameWAL0921WAL-0921WAL 0921
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionUrokinase plasminogen activator surface receptor inhibitors
TargetsUrokinase plasminogen activator surface receptor
Therapy Area/IndicationsRenal Insufficiency, ChronicNephrosis, LipoidGlomerulosclerosis, Focal Segmental +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustraliaUnited Kingdom +[7] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesWalden Biosciences Inc
China Registration ClassN/A

Develop Information

Active CompaniesWalden Biosciences IncUniversity Of Michigan
Inactive CompaniesN/A
Active IndicationsRenal Insufficiency, ChronicNephrosis, LipoidGlomerulosclerosis, Focal Segmental +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A